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Malignant Pure Pulmonary Ground-Glass
Opacity Nodules: Prognostic Implications
Objective: This study was designed to evaluate follow-up results in terms of
patient prognosis for malignant pulmonary nodules depicted as pure ground-
glass opacity (GGO) lesion observed at high-resolution CT (HRCT).
Materials and Methods: Surgical removal for malignant GGO nodules was
accomplished in 58 patients (26 men, 32 women; mean age, 57 years; age
range, 29-78 years). Patient prognoses were assessed by patient clinical status
and the presence of changes in nodule size determined after a follow-up HRCT
examination. Differences in patient prognoses were compared for nodule num-
ber, size, surgical method, change in size before surgical removal, and
histopathological diagnosis by use of Fisher’s exact test and Pearson’s chi-
squared test.
Results: Of the 58 patients, 40 patients (69%) were confirmed to have a bron-
chioloalveolar carcinoma (BAC) and 18 patients (31%) were confirmed to have
an adenocarcinoma with a predominant BAC component. Irrespective of nodule
size, number, treatment method, change in size before surgical removal and
histopathological diagnosis, neither local recurrence nor a metastasis occurred in
any of these patients as determined at a follow-up period of 24 months (range;
12-65 months). Of 14 patients with multiple GGO nodules, all of the nodules were
resected without recurrence in six patients. In the remaining eight patients, the
remaining nodules showed no change in size in seven cases and a decrease in
size in one case as determined after a follow-up CT examination. 
Conclusion: Prognoses in patients with pure GGO malignant pulmonary nod-
ules are excellent, and not significantly different in terms of nodule number, size,
surgical method, presence of size change before surgical removal and
histopathological diagnosis.
pure ground-glass opacity (GGO) nodule is a round, homogeneous and
well-defined hypoattenuating lung lesion with respect to the surrounding
soft-tissue structure such as a vessel that has no patches of completely
obscured parenchyma (1). Kim et al. (2) have reported that approximately 75% of
persistent nodules (with either no change or an increase in diameter for > one month)
were either a bronchioloalveolar cell carcinoma (BAC) or an adenocarcinoma with a
predominant BAC component (adenoCa with BAC). The remaining 25% of nodules
were attributed to atypical adenomatous hyperplasia (AAH) and to a nonspecific
fibrosis or an organizing pneumonia (2, 3). Moreover, most of multiple pure GGO
nodules (8 of 12, 67%) were BACs or adenoCas with BAC (2).
For the management of BACs or adenoCas with BAC that manifest as pure GGO
malignant nodules in the lungs, the appropriateness of limited resection using
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Athoracoscopy for a single malignant GGO nodular lesion
has been validated in several studies (4-7). Mun and
Kohno (8) have demonstrated that the management of
multiple BACs by the use of video-assisted thoracoscopic
surgery (VATS) (multifocal wedge resection when the
nodules are scattered throughout multiple lobes or both
lungs, or a lobectomy when the nodules are localized in a
lobe) yielded satisfactory results. However, resective lung
surgery should be performed when the patient has
reserved lung parenchymal volume. Such treatment may
not be feasible when the patient has many nodules, e.g.,
ten or more nodules. Under these circumstances,
chemotherapy may be a valid treatment option (9).
Therefore, there is ongoing debate concerning the manage-
ment of patients with pure GGO malignant nodule(s),
particularly when the patients have multiple pure GGO
malignant nodules. The purpose of this study was to
evaluate the follow-up results in terms of patient prognosis
for pure GGO malignant pulmonary nodules that are
observed with the use of high-resolution CT (HRCT).
MATERIALS AND METHODS
Our institutional review board approved this retrospec-
tive study with the waiver of patient informed consent, but
written informed consent was acquired from all patients
for the CT study.
Patients
We reviewed all surgical biopsy files recorded from
November 1994 to March 2007 and selected patients who
satisfied the following inclusion criteria. 1) Patients were
included with pulmonary lesions and the descriptive term
“pure GGO nodule(s)” but without any solid or part-solid
nodule as noted on the CT reports. 2) Patients with tissue
biopsy results of a BAC or adenoCa with BAC were
included. 3) Patients who had undergone follow-up CT
studies for at least one year after a histopathological
diagnosis or management of GGO nodules were included.
A GGO nodule (a solid portion < 5% of the nodule
volume) was defined as a discrete pulmonary nodular
abnormality when it was 3 cm or less in diameter seen with
homogeneous attenuation that was not as high as the
surrounding soft-tissue structures. A GGO nodule had
short- and long-axis diameters within a factor of 1.5 of
each other as measured on transverse scans and the GGO
nodule was observed on a successive number of thin-
section CT scans, thereby verifying that the lesion was
spherical. We also included patients with multiple GGO
nodules, one or more of which was confirmed as a BAC or
an adenoCa with BAC.
A total of 58 patients (26 men, 32 women; mean age, 57
years; age range, 29-78 years) were included in the study.
The 58 patients had 106 pure GGO nodules as determined
with the use of HRCT. A single nodule was identified in 44
patients and 14 patients had multiple nodules (five patients
had two nodules, three patients had three nodules, two
patients had four nodules and four patients had five or
more nodules) detected by CT. In the 14 patients with
multiple GGO nodules, histological confirmation of
malignancy, i.e., the presence of a BAC or adenoCa with
BAC was determined for at least two nodules in nine
patients. In the remaining five patients, histological confir-
mation of malignancy was obtained for one of multiple
GGO nodules, and the other nodule(s) were presumed to
be malignant.
Surgical removal of malignant GGO nodule(s) was
accomplished in 58 patients. With regard to the 44 patients
with a single GGO nodule, 32 patients underwent a
lobectomy and 12 patients had wedge resections. Of the 14
patients with multiple GGO nodules, six patients
underwent a lobectomy as all of the nodules were localized
deep in one lobe or predominant nodule(s) of > 10 mm in
diameter were localized in one lobe. Eight patients (includ-
ing three patients who received multiple-site resections)
were treated by wedge resection as the nodules of even
size were scattered in multiple lobes or peripherally in one
lobe. Of these eight patients, one patient with 15 GGO
nodules had undergone chemotherapy with 150 mg/m
2
erlotinib (Tarceva; OSI Pharmaceuticals, Melville, NY)
daily for 30 months after a VATS wedge resection for one
malignant GGO nodule with a peripheral location.
Image Acquisition and Analysis
CT scans were obtained with the helical technique using
scanners from General Electric Medical Systems
(Milwaukee, WI). Units included a single-detector scanner
(HiSpeed Advantage; three patients with eight nodules), a
four-detector scanner (LightSpeed QX/I; 26 patients with
57 nodules), an eight-detector scanner (LightSpeed Ultra;
13 patients with 16 nodules), a 16-detector scanner
(LightSpeed16; 13 patients with 22 nodules) or a 64-
detector scanner (LightSpeed VCT; three patients with
three nodules). Unenhanced scans only were obtained
from two patients with four nodules, and both enhanced
and unenhanced scans were obtained from 56 patients
with 102 nodules. For an enhancement study, 100 mL of
contrast medium (Iomeron 300; Bracco, Milan, Italy) was
administered intravenously. For all patients, the scanning
parameters were 120 kVp and 70-200 mA. For a single
helical CT, a section thickness of 7 mm, a pitch of 1 and a
reconstruction interval of 7 mm were used for scanning
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of 10-40 mm, a beam pitch of 1.3-1.5 and a reconstruction
interval of 2.5-5.0 mm were used. For single helical CT,
additional HRCT scans (1.0-2.5 mm section thickness)
were obtained for all of the GGO nodules examined
whereas HRCT scans (1.25-2.5 mm) were acquired by
retrospective reconstruction of raw data for the 4-64 slice
CT imaging. All image data were reconstructed using a
bone algorithm.
Two chest radiologists (with two and 18 years experi-
ence, respectively) assessed the CT scans retrospectively.
Decisions on the CT findings were reached by consensus.
CT scans were assessed in terms of size (the longest
diameter), location (six lobes, including the lingular
division of the left upper lobe as an isolated lobe) and the
number of the GGO nodules. The presence or absence of
hilar and mediastinal nodal enlargement was evaluated.
CT scans were usually obtained at three- or six-month
intervals. Serial CT scans, were available before surgical
resection for all patients (follow-up range, 3-72 months;
mean, 11 months; median, six months). The presence or
absence of size change (the longest diameter when a
nodule was single or the longest diameters of the two
largest nodules when there were two or more nodules) for
the GGO nodules before surgical removal could be
evaluated. In addition, any change in attenuation of the
GGO nodules was evaluated visually.
Serial CT scans were also available after surgical removal
at three or six-month intervals for all patients (follow-up
range, 12-65 months; mean, 24 months; median, 21
months). We investigated the presence or absence of local
recurrence or a distant metastasis and interval changes in
size for the remaining GGO nodules (when none of the
nodules could be removed for technical reasons). Patient
fates were assessed during the follow-up period.
CT-Pathological Comparisons
Entire sections of resected tissues were fixed in formalin
and were embedded in paraffin. Several 4-μ m-thick
sections taken from the equator of the lesions were stained
with hematoxylin and eosin and were examined by light
microscopy. An experienced lung pathologist (with 15
years of lung pathology experience) interpreted all of the
tissue sections. The histopathological diagnoses were classi-
fied as BAC, adenoCa with BAC and AAH according to
the revised World Health Organization histological classifi-
cation system (10).
Ten patients had a previous malignant tumor history.
Two patients had an adenocarcinoma of the lung, two
patients had a papillary carcinoma of the thyroid, three
patients had an adenocarcinoma of the colon, one patient
had a gastric cancer, one patient had a ductal adenocarci-
noma of the distal common bile duct and one patient had
an infiltrating ductal carcinoma of the breast. For these ten
patients, histological differences between BAC or adenoCa
with BAC and previous cancer cell types were clearly
shown after a histopathological examination or, if
necessary, by immunohistochemical staining for thyroid
transcription factor-1 (TTF-1), CK20 or CK7 (11, 12).
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Table 1. Comparison of Demographic Data between Patients with Single or Multiple Pure Ground-Glass Opacity Malignant
Nodule(s)
Characteristics Single Mal GGO Nodule (n = 44) Multiple Mal GGO Nodules (n = 14) P values
Size of largest nodule 0.641
< 10 mm 22 6
> 10 mm 22 8
Surgical methods 0.056
Lobectomy 32 6
Wedge resection 12 8
Change in size before surgical removal 0.457
No change 36 10
Increase 8 4
Pathological diagnosis 0.327
BAC 32 8
AdenoCa with predominant 
BAC component 12 6
Gender 0.160
Men 22 4
Women 22 10
Note.─ GGO = ground-glass opacity, BAC = bronchioloalveolar cell carcinoma, AdeonoCa = adenocarcinoma, mal = malignantStatistical Analyses
Demographic data in terms of the largest nodule size
(nodules of < 10 mm and > 10 mm in diameter), surgical
method, presence of a size change before surgical removal,
pathological diagnosis and gender of patients were
compared between patients with single or multiple
malignant ground-glass opacity nodules by use of Fisher’s
exact test and Pearson’s chi-squared analysis.
Patient prognoses were assessed by analyzing the
presence or absence of local recurrence or a distant
metastasis (by assessing patient symptoms and signs,
follow-up CT findings and laboratory data), and changes in
the size of the remaining GGO nodules (for patients with
multiple malignant GGO nodules where all nodules could
not be removed surgically) after follow-up HRCT imaging.
If there was any recurrence or a metastasis, differences in
patient prognoses were compared in terms of nodule
number (single versus multiple), size, surgical method
used, change in size before surgical removal and
histopathological diagnosis.
RESULTS
Histological Diagnoses and Demographic Findings
Histological confirmation was performed on 73 nodules
from 58 patients. Of the 73 nodules, 47 were BACs (range
of nodule diameter, 6-28 mm; mean, 13 mm; median, 12
mm), 21 nodules were adenoCas with BAC (range of
nodule diameter, 5-28 mm; mean, 14 mm; median, 12
mm), and five nodules were AAH (range of nodule
diameter, 3-5 mm; mean, 4 mm; median, 4 mm). As for
the GGO malignant nodules except for AAH, 28 (48%)
patients had nodules < 10 mm in diameter and 30 patients
(52%) had at least one nodule > 10 mm in diameter.
Patient demographic data for single GGO nodules were
not significantly different from data for multiple malignant
GGO nodules (Table 1). 
Ground-glass opacity nodule(s) were identified on a CT
scan in two patients who underwent chest CT for respira-
tory symptoms, in ten patients who underwent a lung
cancer screening and incidentally in 46 patients without
pulmonary symptoms who underwent a chest CT examina-
tion for other reasons.
Patients with a Single Ground-Glass Opacity
Malignant Nodule (n = 44)
Thirty-two patients had BACs and 12 patients had
adenoCas with BAC. Twenty-two patients had a nodule <
10 mm in diameter and 22 patients had a nodule > 10 mm
in diameter (Table 1). Thirty-six patients had tumors that
showed no change in size (over a follow-up period of 1-36
months). Eight patients had tumors that showed an
increase in size. There was a 2 mm increase in diameter for
six patients over a follow-up period of six to 45 months, a
3 mm increase in diameter for one patient over a follow-up
period of 72 months and a 5 mm increase in diameter for
one patient over a follow-up period of 42 months before
surgical removal. The follow-up period range was 3-72
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Table 2. Pathology, High-Resolution CT Findings and Prognoses in 14 Patients with Multiple Pure Ground-Glass Opacity
Malignant Nodules
Patient
Pathology of  No. of Nodules  Change in Size/  FU Period  Change in Size of  Patient 
No.
Predominant  (involved  FU (mos) Period Tx Given (mos)  Remaining Nodule(s)  Condition at 
Nodule lobes) Before Tx after Tx During F/U after Tx Latest F/U
1A W B 02 (1) 3 mm increase/18 Wedge resection (x 2) 12 N/A Good
2 BAC 15 (3) No/1 Wedge resection and 
Chemotherapy 24 Decrease Good
3 BAC  07 (3) No/2 Wedge resection (x 2) 30 No change Good
4 BAC  05 (1) No/3 Lobectomy 41 N/A Good
5 BAC  02 (2) No/3 Wedge resection 24 No change Good
6 BAC  03 (2) No/3 Wedge resection 18 No change Good
7 BAC  03 (3) No/2 Lobectomy 20 No change Good
8 BAC  02 (2) No/2 Wedge resection (x 2) 12 N/A Good
9A W B 02 (1) No/5 Lobectomy 13 N/A Good
10 BAC  04 (2) No/6 Wedge resection 18 No change Good
11 AWB  02 (1) 2 mm increase/27 Lobectomy 12 N/A Good
12 AWB  03 (1) 3 mm increase/36 Wedge resection 15 No change Good
13 AWB  08 (1) 2 mm increase/66 Lobectomy 18 N/A Good
14 AWB  04 (2) No/1 Lobectomy 15 No change Good
Note.─ AWB = adenocarcinoma with predominant bronchioloalveolar carcinoma component, BAC = bronchioloalveolar carcinoma, No. = number, 
Sx = symptom, F/U = follow up, Tx = treatment, mos = months, x 2 = two resection sites, N/A = not applicable as all tumors were resected.months; mean, nine months; median, six months. The
attenuation value within a nodule did not change in any
nodule.
Of the 32 patients who underwent a lobectomy for a
single malignant GGO nodule, no patient had a nodal
metastasis in the hilum or the mediastinum. 
Neither local recurrence nor a metastasis occurred in any
of these patients during the follow-up period (range, 12-65
months; mean, 25 months; median 21 months).
Patients with Multiple Malignant Ground-Glass
Opacity Nodules (n = 14)
Table 2 summarizes the diagnostic methods, HRCT
findings for the nodules, previous follow-up study results,
management and follow-up results for patients with
multiple malignant GGO nodules. Eight patients had
BAC(s) and six patients had at least one adenoCa with
BAC. Six patients had nodules < 10 mm in diameter and
eight patients had at least one nodule > 10 mm in
diameter. Ten patients (71%) had tumors that showed no
change in size (over a follow-up period of 1-6 months).
Four patients (29%) had tumors where at least one nodule
had an increase in size. There was a 2 mm increase for two
patients over a follow-up period of 27-66 months and a 3
mm increase for two patients over a follow-up period of
18-36 months before surgical removal. The follow-up
period range was 3-66 months; mean, 15 months; median,
six months (Figs. 1, 2). The attenuation value within a
nodule did not change in any nodule.
Of six patients who underwent a lobectomy, none of the
patients had a hilar or mediastinal nodal metastasis. All of
the multiple nodules were resected in the six patients
without recurrence. In the remaining eight patients, the
remaining GGO nodules showed no change in size for
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Fig. 1. Multiple (n = 2) ground-glass
opacity nodules in right upper lobe; one
nodule was identified as adenocarci-
noma with predominant bronchioloalve-
olar carcinoma component (arrow) and
other nodule was identified as bronchi-
oloalveolar cell carcinoma (arrowhead).
Patient was 59-year-old man (patient
number 11 in Table 2).
A, B. Transverse lung window CT (1.25-
mm section thickness) scans obtained
15 months before lobectomy for ground-
glass opacity nodules show two ground-
glass opacity nodules (arrow and
arrowhead, respectively) in right upper
lobe.
C, D. CT (2.5-mm section thickness)
scans obtained at similar levels to A and
B and at time of surgery demonstrate
that nodules have increased in size.
Follow-up CT scans (data not shown)
obtained 21 months after right upper
lobectomy showed no evidence of local
recurrence or distant metastasis.seven patients, and showed a decrease in size (the largest
nodule; from 32 to 20 mm in diameter over a follow-up
period of 24 months) in one patient (who received
chemotherapy) after follow-up CT imaging (Fig. 3).
Neither local recurrence nor a metastasis was detected in
any of these patients after a follow-up evaluation (range,
12-41 months; mean, 20 months; median, 18 months).
Prognoses versus Clinical or Imaging Features
Neither local recurrence nor a metastasis occurred in any
patient with pure GGO malignant nodule(s) as determined
after a follow-up evaluation for at least more than one
year, irrespective of the nodule number, size, treatment
(surgical) method and histopathological diagnosis.
DISCUSSION
It is currently accepted that limited resection (e.g., a
wedge resection or segmentectomy) is the appropriate
management strategy for patients with a nonmucinous
BAC or an adenoCa with BAC when the lesion appears as
a pure GGO nodule (4-7). However, there has been some
debate on the management of multiple pure GGO
malignant nodules. Multiple limited resections may be
feasible if patients have double or triple malignant GGO
nodules and pulmonary functional reserve. However,
Prognostic Implications of Malignant Pure Pulmonary Ground-Glass Opacity Nodules
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Fig. 2. Multiple (total 8) ground-glass opacity nodules in right upper lobe; two nodules were identified as adenocarcinomas with 
predominant bronchioloalveolar carcinoma component, five nodules were identified as bronchioloalveolar carcinomas and one nodule
was identified as atypical adenomatous hyperplasia. Patient was 49-year-old woman (patient number 13 in Table 2).
A-C. Transverse lung window CT (2.5-mm section thickness) scans obtained through right upper lobe show pure ground-glass opacity
nodules (arrows), at least four in number in right upper lobe.
D-F. CT scans (1.25-mm section thickness) obtained at similar levels to and 27 months after A-C demonstrate that most of ground-glass
opacity nodules (arrows) have increased in diameter. Follow-up CT scans (data not shown) obtained 18 months after right upper
lobectomy disclosed no evidence of local recurrence or distant metastasis.
DEFother options should be considered when patients have
five or more malignant GGO nodules that are scattered in
both lungs with multi-lobar involvement. In our institution,
when multiple malignant GGO nodules are localized deep
in one lobe or when predominant nodule(s) of > 10 mm in
diameter are localized in one lobe, a lobectomy is usually
performed. However, when nodules of even size are
scattered in multiple lobes or peripherally in one lobe,
multiple-site wedge resections are executed.
In one study (9), chemotherapy has been suggested as an
alternative therapeutic option. In our study, a patient who
had more than 15 malignant GGO nodules in both lungs
was treated with chemotherapy (150 mg/m
2 Tarceva daily
for 30 months). For this particular patient, most of the
nodules showed a decrease in size. Furthermore, no
additional nodules occurred during the follow-up period of
> two years.
In our study, there was no recurrent case after treatment
even for patients with multiple GGO nodules (14 patients,
24%). This result concurs with findings of Kodama and
colleagues (13). Moreover, in patients who had GGO
nodules that remained after surgical resection of one or
some of GGO nodules (because all of the nodules could
not be resected due to bilateral lung or multi-lobar involve-
Park et al.
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Fig. 3. Multiple (total 15 GGO nodules) malignant ground-glass opacity nodules in 56-year-old woman (patient number 2 in Table 2) who
underwent wedge resection for one of nodules in right lower lobe and who received additional chemotherapy.
A-C. Transverse lung window CT (5.0-mm section thickness) scans obtained at levels of thoracic inlet (A), azygos arch (B) and inferior
pulmonary vein (C), respectively, show multiple pure ground-glass opacity nodules (arrows) of variable size in both lungs. Wedge
resection from one of small ground-glass opacity nodules identified presence of bronchioloalveolar cell carcinoma. Subsequently, patient
received chemotherapy.
D-F. Follow-up CT (1.25-mm section thickness) scans obtained 24 months after A-C (with chemotherapy) demonstrate that most
nodules (arrows) have decreased in size. In addition, no new nodules appeared during follow-up period. Curved arrow indicates previous
wedge resection site.ment of the nodules), the remaining nodules did not show
a change in size as depicted on follow-up CT images.
Therefore, even for multiple malignant GGO nodules,
limited resection or follow-up without specific treatment
after surgical diagnosis of the lesions may be sufficient as
an appropriate management method. However, our results
should be interpreted with caution as the follow-up period
was short and the number of included cases was small.
Given the excellent prognosis (without mediastinal nodal
metastases or without recurrence) of single or multiple
malignant GGO nodules, limited resection or imaging
follow-up studies without specific treatment after the
diagnosis for these nodules may be sufficient. Currently,
no optimum follow-up intervals for persistent pure GGO
nodules have been reported. As pure GGO malignant
nodules have a longer volume doubling time as compared
with malignant solid or part-solid nodules (14, 15), follow-
up studies with intervals of 12 months should be validated.
In our institution, a single pure GGO nodule of 10 mm or
less is repeatedly evaluated using HRCT at 12-month
intervals.
However, studies have reported that the appearance of a
solid portion within a pure GGO area indicates a malignant
tumor with a high potential of a loco-regional lymph node
or distant organ metastasis (16, 17). Thus, with an option
of simple follow-up for these malignant GGO nodules by
the use of CT studies particularly when the nodules are >
10 mm in diameter, short-term (e.g., at 3- or 6-month
intervals) follow-up evaluation with the use of CT imaging
seems more appropriate than a long-term (e.g., at 12-
month intervals) follow-up study. 
Mun and Kohno (8) experienced newly developed GGO
nodules in seven (26%) of 27 patients with multiple BACs
after surgical removal of previously present GGO nodules
(median follow-up period, 46 months; range 3-81 months).
These new lesions were seen as pure GGO nodules of 3
mm or less in diameter (BACs or AAH). These lesions
were not invasive in any of the cases, and the patients are
still being followed up by the use of CT imaging. In our
patients, recurrent GGO nodules were not observed in any
patient. This difference may be ascribed to the relatively
short follow-up period (range, 12-41 months; mean, 20
months; median, 18 months) in our study.
This study has several limitations. First, the study was
performed as a retrospective review. A randomized
controlled trial study is needed, particularly for patients
with multiple pure GGO malignant nodules. Second,
although we included all 14 patients with multiple GGO
nodules, this number is still small. In addition, cases were
not managed homogeneously. Most patients received
surgical resection, while one patient with 15 nodules or
more received chemotherapy after a wedge resection.
In conclusion, according to the results of our study,
prognoses in patients with malignant pure pulmonary
GGO nodules are excellent, and neither local recurrence
nor metastases occurs irrespective of nodule number, size,
surgical method, presence of size change before surgical
removal and histopathological diagnosis. Even for multiple
pure GGO malignant nodules or for pure GGO malignant
nodule(s) > 10 mm in diameter, minimally invasive surgery
with preservation of lung volume and adequate imaging
follow-up studies are recommended for both diagnosis and
treatment. Another treatment option may be to perform
follow-up CT studies only until a solid portion appears
within the pure area of ground-glass opacity in order to
determine when the surgical removal of the nodules is
necessary. However, our results and suggested treatment
options for the management of pure GGO malignant
nodules are the products of a still evolving study. Long-
term follow-up and ideally randomized controlled trial
study results remain to be determined.
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